Hugel
Leading South Korean biopharmaceutical company specializing in botulinum toxin products (Letybo/Botulax) and dermal fillers for aesthetic and therapeutic applications. Publicly traded on KOSDAQ.
Notes
Hugel is a leading South Korean biopharmaceutical company specializing in botulinum toxin products and dermal fillers. The company's flagship product Letybo (botulinum toxin type A) competes globally with Allergan's Botox and other botulinum toxin brands.
Founded in 2001, Hugel has become one of the largest aesthetic medicine companies in Asia. The company's botulinum toxin products are approved and marketed in numerous countries under various brand names (Botulax in Korea, Letybo in international markets).
Hugel has attracted investment from Bain Capital Life Sciences and other global investors as it expands its international presence, particularly in the United States and European markets where the aesthetic medicine market continues to grow.
Team
- Son Ji-hoon - CEO
- Leadership team with extensive pharmaceutical and aesthetics industry experience
Additional Research Findings
- Founded in 2001 in Seoul, South Korea
- Publicly traded on KOSDAQ (Korea)
- Bain Capital Life Sciences investment
- Leading botulinum toxin manufacturer in Korea
- Products: Letybo/Botulax (botulinum toxin), dermal fillers
- Expanding into US and European markets
- Competition with Allergan (Botox), Galderma, Evolus
- GMP manufacturing facilities in Korea
- Growing international market share in aesthetics